These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
252 related articles for article (PubMed ID: 33012187)
1. Developing strategies to reduce the duration of therapy for patients with myeloproliferative neoplasms. Bar-Natan M; Hoffman R Expert Rev Hematol; 2020 Nov; 13(11):1253-1264. PubMed ID: 33012187 [TBL] [Abstract][Full Text] [Related]
2. Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure? Hasselbalch HC; Holmström MO Semin Immunopathol; 2019 Jan; 41(1):5-19. PubMed ID: 30203226 [TBL] [Abstract][Full Text] [Related]
3. Current clinical strategies and emergent treatment landscapes in leukemic transformation of Philadelphia-negative myeloproliferative neoplasms. Abruzzese E; Niscola P Expert Rev Hematol; 2020 Dec; 13(12):1349-1359. PubMed ID: 33226274 [No Abstract] [Full Text] [Related]
4. Synergistic Cytotoxic Effect of Busulfan and the PARP Inhibitor Veliparib in Myeloproliferative Neoplasms. Patel PR; Senyuk V; Rodriguez NS; Oh AL; Bonetti E; Mahmud D; Barosi G; Mahmud N; Rondelli D Biol Blood Marrow Transplant; 2019 May; 25(5):855-860. PubMed ID: 30615982 [TBL] [Abstract][Full Text] [Related]
5. Therapeutic options for leukemic transformation in patients with myeloproliferative neoplasms. Khan M; Siddiqi R; Gangat N Leuk Res; 2017 Dec; 63():78-84. PubMed ID: 29121538 [TBL] [Abstract][Full Text] [Related]
6. Use of granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with hydroxyurea as post-transplant therapy in chronic myelogenous leukemia patients autografted with unmanipulated hematopoietic cells. Carlo-Stella C; Regazzi E; Andrizzi C; Savoldo B; Garau D; Montefusco E; Vignetti M; Mandelli F; Rizzoli V; Meloni G Haematologica; 1997; 82(3):291-6. PubMed ID: 9234574 [TBL] [Abstract][Full Text] [Related]
8. Role of hematopoietic stem cell transplantation in patients with myeloproliferative disease. Salit RB; Deeg HJ Hematol Oncol Clin North Am; 2014 Dec; 28(6):1023-35. PubMed ID: 25459177 [TBL] [Abstract][Full Text] [Related]
9. Current Concepts of Pathogenesis and Treatment of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms. Zeeh FC; Meyer SC Hamostaseologie; 2021 Jun; 41(3):197-205. PubMed ID: 34192778 [TBL] [Abstract][Full Text] [Related]
10. [Interferon-alpha in the treatment of myeloproliferative diseases]. Kissová J Vnitr Lek; 2019; 65(11):699-703. PubMed ID: 31906676 [TBL] [Abstract][Full Text] [Related]
11. Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone. Kiladjian JJ; Giraudier S; Cassinat B Leukemia; 2016 Apr; 30(4):776-81. PubMed ID: 26601783 [TBL] [Abstract][Full Text] [Related]
12. IFN-α Is Effective for Treatment of Minimal Residual Disease in Patients with Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: Results of a Registry Study. Mo XD; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ Biol Blood Marrow Transplant; 2017 Aug; 23(8):1303-1310. PubMed ID: 28457953 [TBL] [Abstract][Full Text] [Related]
15. Busulfan is effective second-line therapy for older patients with Philadelphia-negative myeloproliferative neoplasms intolerant of or unresponsive to hydroxyurea. Douglas G; Harrison C; Forsyth C; Bennett M; Stevenson W; Hounsell J; Ratnasingam S; Ritchie D; Ross DM; Grigg A Leuk Lymphoma; 2017 Jan; 58(1):89-95. PubMed ID: 27454522 [TBL] [Abstract][Full Text] [Related]
17. Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: proceedings from the 6th International Post-ASH Symposium. Abdel-Wahab O; Pardanani A; Bernard OA; Finazzi G; Crispino JD; Gisslinger H; Kralovics R; Odenike O; Bhalla K; Gupta V; Barosi G; Gotlib J; Guglielmelli P; Kiladjian JJ; Noel P; Cazzola M; Vannucchi AM; Hoffman R; Barbui T; Thiele J; Van Etten RA; Mughal T; Tefferi A Am J Hematol; 2012 May; 87(5):562-8. PubMed ID: 22460584 [TBL] [Abstract][Full Text] [Related]
18. New Horizons in Myeloproliferative Neoplasms Treatment: A Review of Current and Future Therapeutic Options. Penna D Medicina (Kaunas); 2021 Oct; 57(11):. PubMed ID: 34833399 [TBL] [Abstract][Full Text] [Related]
19. Safety of autologous hematopoietic stem cell transplantation in patients with multiple myeloma and chronic renal failure. Tosi P; Zamagni E; Ronconi S; Benni M; Motta MR; Rizzi S; Tura S; Cavo M Leukemia; 2000 Jul; 14(7):1310-3. PubMed ID: 10914557 [TBL] [Abstract][Full Text] [Related]
20. Monitoring Minimal Residual Disease in the Myeloproliferative Neoplasms: Current Applications and Emerging Approaches. Haslam K; Langabeer SE Biomed Res Int; 2016; 2016():7241591. PubMed ID: 27840830 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]